Kimmel C A, Generoso W M, Thomas R D, Bakshi K S
Reproductive and Developmental Toxicology Branch, U.S. Environmental Protection Agency, Washington, DC 20460.
Toxicol Appl Pharmacol. 1993 Apr;119(2):159-65. doi: 10.1006/taap.1993.1056.
Recent advancements in molecular developmental biology afford an opportunity to apply newly developed tools for understanding the mechanisms of both normal and abnormal development. Although a number of agents have been identified as causing developmental abnormalities, our knowledge of the mechanisms by which these alterations occur is minimal. This paper reviews some of the important issues in this area that may lead to understanding the basic developmental processes and mechanisms by which toxic agents may interfere with these processes. Approximately 70% of developmental defects are of unknown etiology. Historically, it has been assumed that these defects were most likely to be induced by exposure to chemical or physical agents during organogenesis. There is now convincing evidence that exposure during preorganogenesis developmental stages to certain agents can also lead to fetal abnormalities as a result of direct damage to the exposed early conceptus. Thus, pre- or postimplantation exposure of the developing conceptus to toxicants may result in a "derailment" in the genetic control of development and the coordinated cascade of events that occur during normal development. For example, developmental abnormalities may be induced by disrupting the coordinated expression of developmental genes involved in genomic imprinting, cell lineage specification, cell mixing and recognition, cell-cell interaction, cell migration and differentiation, and segmentation, depending on the time of exposure. Because of our lack of knowledge about the molecular and cellular bases of chemically induced abnormal development, a number of assumptions are currently used in the process of evaluating and interpreting data for developmental toxicity studies. The study of mechanisms of normal and abnormal development and the pharmacokinetic-pharmacodynamic relationships in humans and experimental animals are key to the development of appropriate risk assessment assumptions and dose-response models for characterizing the risk for developmental toxicity in the human population. This article summarizes the discussions of the workshop on developmental abnormalities organized by the Committee on Toxicology of the National Research Council.
分子发育生物学的最新进展为应用新开发的工具来理解正常和异常发育机制提供了契机。尽管已确定多种因素可导致发育异常,但我们对这些改变发生机制的了解却微乎其微。本文综述了该领域的一些重要问题,这些问题可能有助于理解基本的发育过程以及有毒物质干扰这些过程的机制。约70%的发育缺陷病因不明。从历史上看,人们一直认为这些缺陷很可能是在器官形成期接触化学或物理因素所致。现在有令人信服的证据表明,在器官形成前的发育阶段接触某些物质,由于对早期着床前胚胎的直接损害,也会导致胎儿异常。因此,发育中的胚胎在着床前或着床后接触毒物,可能会导致发育的基因控制以及正常发育过程中发生的一系列协调事件出现“脱轨”。例如,根据接触时间的不同,发育异常可能是由于破坏了参与基因组印记、细胞谱系特化、细胞混合与识别、细胞间相互作用、细胞迁移与分化以及分割等发育基因的协调表达而引起的。由于我们对化学诱导的异常发育的分子和细胞基础缺乏了解,目前在评估和解释发育毒性研究数据的过程中使用了一些假设。研究正常和异常发育的机制以及人类和实验动物体内的药代动力学-药效学关系,是制定适当的风险评估假设和剂量反应模型以描述人群发育毒性风险的关键。本文总结了由美国国家研究委员会毒理学委员会组织的关于发育异常研讨会的讨论内容。